International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 47 No. 1 October 2024, pp. 248-255

Management of Hypertension, Fatty Liver, and Stage 2 CKD in a 65-Year-Old Male

[1]Savitran Eshwar , [2]Sameera Bazal Mohamed, [3]Dr. Sana Fathima, [4]Savitran Eshwar, [5]Sameera Bazal Mohamed

[1]Medical University of Lublin, MD,LUBLIN , Poland,

[2]Tbilisi State Medical University

[3]Gulf Medical University , Ajman,UAE

[4]Lublin,Poland
eswarsavitran2023@gmail.com

[5]Tbilisi, Georgia
sameera.tsmu@gmail.com

Corresponding Author: Dr.Sana Fathima; dr.sanafathima@gmu.ac.ae

Abstract – The analysis of the elderly patients as their group integrates the highest instance of comorbidities poses a challenge in a multi-faceted management approach. The case study is aimed to provide an insight into managing a 65 year old male diagnosed with hypertension, chronic renal disease and fatty liver disease along with new symptoms of deterioration.
Presentation: This patient has a history of hypertension for 30 years, trained stage 2 CKD for 3 years, and developed fatty liver disease 5 years ago. He underwent coronary angioplasty with stenting at the retirement age of 55 years. Over the last six months, there has been development of progressive weakness, followed by weight gain and swelling of the legs. Despite multiple antihypertensive medications, the blood pressure remains high.
Physical Examination and Investigations: BP 150/90 mmHg, mild leg swelling & Headache and mildly enlarged liver were noted on physical examination. Creatinine level was 1.8 mg/dl, eGFR 50 ml/min/1.73m² and liver enzymes were elevated in laboratory tests. Studies showed fatty liver, no renal obstruction, and normal heart function after the stent insertion.
Management: The plan, after a while, will include a strictly optimized antihypertensive therapy regimen, lifestyle modification measures including a low salt diet and physical activity. On the side of the other medications, statin treatment should be kept at all times. It should not be forgotten that the kidney and liver parameters should be checked regularly as they have a direct relation with cardiovascular health.

Keywords – Hypertension, Chronic Kidney Disease, Fatty Liver Disease, Cardiovascular Risk, Management, Lifestyle Changes.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 47 No. 1 October 2024, pp. 248-255

I. CASE PRESENTATION

A 65-year-old male with known history of hypertension for 30 years who is in the third decade of chronic renal disease and also suffers from liver disease and status post coronary artery stenting.

Chief Complaints:

The patient complained of weakness, increased weight, and swelling of the legs which had been progressive over the past six months. Blood pressure was persistently high even with the patient being on numerous antihypertensive medications.

History of Present Illness:

Hypertension was diagnosed at 35 years and was on numerous medications and it is being maintained. At the age of 55 years, the patient had cardiac stenting due to coronary artery disease. Fatty liver disease was diagnosed 5 years back, and 3 years back stage 2 chronic kidney disease was diagnosed There has been increased fatigue together with edema and weight gain reported, other complaints include symptomatology.

Examination Findings:

On examination: BP: 150/90 mmHg.Legs showed mild swelling.

Abdominal examination showed mild hepatomegaly.

There were no important findings on the cardiovascular exam and renal examination.

Laboratory Investigations:

Creatinine: 1.8 mg/dl (considered in a stage of renal failure,Normal range- 0.7 to 1.3 mg/dl)

eGFR: 50 ml/min/1.73m2 (Stage 2 CKD).

Increased levels of AST and ALT. In cross section, urinalysis mild proteinuria was observed.

Imaging Studies:

Ultrasonography of the abdomen revealed fatty liver.

Renal ultrasound was unremarkable without any obstructive pathology.

Echocardiogram showed normal functions of the heart after stenting.

Adjust antihypertensive treatment to manage blood pressure and safeguard renal function.

Inference:

To control fatty liver and hypertension, lifestyle changes such as a lower salt diet and more physical exercise are recommended.

Continue statin medication to manage cholesterol and lower cardiovascular risk.

Regular monitoring of kidney, liver, and cardiovascular function.

Conclusion: This is a complicated case of a patient with various chronic diseases, including hypertension, chronic renal disease, and fatty liver disease, who is at high risk for cardiovascular events. Comprehensive therapy, including pharmaceutical modifications and lifestyle interventions, is critical for improving long-term outcomes.

II. INTRODUCTION

It is not uncommon to deal with multiple chronic diseases, including HTN, CKD, and fatty liver, all at the same time. All too often these disorders feed off one another to make things worse and even more challenging to treat. Successful management necessitates integrated therapy integrating effective pharmacologic intervention with personalized lifestyle adjustments. Introduction We present

this case of a 65-year-old gentleman with several chronic medical conditions, along with extensive multidisciplinary management. We highlight the challenges presented by concurrent chronic illnesses while illustrating benefits to outcome optimization when all elements are treated comprehensively through the approach of patient-centered care.

III. OBJECTIVE

The aim is to highlight an integrated approach to managing chronic conditions for improved patient outcomes.

IV. LITERATURE REVIEW

Introduction: In the patients with multiple chronic diseases, including hypertension, CKD, and fatty liver disease, the management process requires a thorough understanding of how these diseases interact and affect each other. This literature review looks at the current approaches and problems encountered in these complex cases and underscores the importance of an integrated treatment strategy.

Hypertension and Chronic Kidney Disease: Hypertension is a well-documented risk factor for the development and progression of CKD. Some studies revealed that untreated hypertension could be a catalyst for the impairment of the kidneys, and as a result, it could cause heart disorders (Mancia et al., 2013).

The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines advise on the need for strict blood pressure control in order to decrease kidney disease progression and reduce the risk of cardiovascular issues (KDIGO, 2020). Nevertheless, the successful regulation of optimal blood pressure may sometimes be very demanding for patients with coexisting CKD, hence the need for personal treatment plans and frequent check-ups.

Fatty Liver Disease: Non-alcoholic fatty liver disease (NAFLD) is a well-established comorbidity in patients with CKD and hypertension. NAFLD can lead to high levels of blood pressure which along with other metabolic syndromes further worsens the situation both for CKD and cardiovascular risk (Younossi et al., 2018). Lifestyle changes including but not limited to weight loss through diet change and increased physical activity are key to the disease management. This way patients with obesity or other associated metabolic abnormalities will also get benefits of those interventions (Chalasani et al., 2018).

Cardiovascular Risk and Management: Patients who have a history of coronary artery disease (CAD), like those who got stents, face a higher chance of more heart problems. Doctors often give statins to keep cholesterol in check and lower heart risks for these patients (Collins et al. 2016). To improve how patients do, we need care plans that look at both heart risks and how to handle CKD and fatty liver disease together.

Managing individuals with many chronic health issues necessitates a thorough and balanced approach. This technique should include medication and lifestyle changes to effectively treat conditions such as high blood pressure, chronic kidney disease (CKD), and non-alcoholic fatty liver disease (NAFLD) (Kovesdy et al. 2017). According to research, synchronizing these aspects leads to significantly better patient outcomes. Regular follow-ups and collaboration among multiple healthcare providers are critical for changing treatment regimens and achieving the best outcomes. Ongoing research is constantly revealing new insights and developing creative techniques to improve the treatment of these complicated individuals, resulting in better health outcomes and quality of life.

V. DESCRIPTION

A 65-year-old man comes in with a complicated medical history. He was diagnosed with hypertension at the age of 35 years and has since been taking different antihypertensive medications over the last three decades. Due to persisting symptoms USG, Lab tests and examinations revealed stage 2 chronic kidney disease at the age of 62 years and Fatty liver disease at the age of 60years. The past medical history is significant for a coronary artery stent placement done ten years ago secondary to coronary artery disease.

In the past six months, the patient presented with lower leg swelling, weight gain, and weakness. Multiple antihypertensive drugs have failed to reduce his blood pressure. The patient states that he does not feel short of breath or experience any chest pain but complains of extreme fatigue and discomfort from edema.

International Journal of Progressive Sciences and Technologies (IJPSAT)
ISSN: 2509-0119.

https://ijpsat.org/
Vol. 47 No. 1 October 2024, pp. 248-255

On physical examination, his blood pressure was 150/90 mmHg. Abdominal examination revealed mild bilateral lower limb edema and a slightly enlarged liver. There were no remarkable findings on renal or cardiovascular examinations.

The laboratory investigations pointed to a glomerular filtration rate (eGFR) of 50 mL/min/1.73 m², which confirmed CKD stage 2, and a serum creatinine level of 1.8 mg/dL consistent with decreasing renal function. There were elevated AST and ALT levels during the liver tests, indicating hepatic dysfunction. A minor case of proteinuria on urinalysis suggested renal impairment.

There was an abdominal ultrasound that formed part of the imaging studies and identified a fatty liver. Renal ultrasound did not find any obstructive pathology. An echocardiogram revealed that cardiac function was preserved after coronary artery stenting.

The patient's treatment is oriented towards modifying his antihypertensive medication to better manage blood pressure and avoid future kidney damage.

To deal with fatty liver disease together with hypertension, some lifestyle changes like low-sodium diets, as well as more exercises, are recommended.

Future cardiovascular risks may be reduced through the use of statins for cholesterol control. Monitoring renal, hepatic, cardiovascular functions regularly is vital to deal with their multiple chronic diseases.

The difficulties in treating a patient with several chronic conditions, such as hypertension, chronic renal disease, fatty liver disease, are demonstrated by this case. Due to the patient's elevated cardiovascular risk, a multidisciplinary strategy is essential to optimize long-term outcomes. This approach should include both lifestyle modifications and pharmaceutical adjustments.

VI. DISCUSSION

Main findings:

This case illustrates the challenges in managing a 65-year-old man with coronary artery disease after stenting, uncontrolled hypertension, chronic kidney disease (CKD), and fatty liver disease (NAFLD). His blood pressure remains high even after the use of several antihypertensive drugs; this was likely because of the synergy of CKD with hypertension. Conditions with such symptoms as fatigue, raised liver enzymes, and edema in the legs are quite complex due to managing multiple comorbidities together.

Possible Reasons and Consequences:

Chronic kidney disease often exacerbates one another; poorly controlled hypertension accelerates the progression of renal failure. The patient's blood pressure remains at 150/90 mmHg after medication therefore, the current regimen is inadequate. He should be prescribed ACE inhibitors or ARBs for not only his hypertension but also his proteinuria, a key condition that hinders the progression of CKD. Fluid retention is by far the most common symptom of chronic kidney disease and can easily be controlled with loop diuretics.

Due to his history of coronary artery stenting, the patient remains at high risk for future cardiovascular events. Maintaining the patency of the stent and preventing thrombotic events require continued statin medication and antiplatelet treatment.

Strengths and Limitations:

The strengths of this case report lie in its clear emphasis of team care and specifically pharmacological management and lifestyle interventions that are so important in the management of such comorbidities in the real world practice. One of the major advantages is that treatment and prevention are personalized, with fine tuning of antihypertensive drugs and dietary and exercise regimes. Specific examples include the KDIGO guideline for management of kidney disease or the use of statin in primary prevention of cardiovascular events. Furthermore, the report defines the research gaps, to continue the research on the effective management of patients with both conditions. This too makes it clinically relevant because it is patient centered and more focused, not only on disease, but on quality of life by giving proper care and close follow up.

One limitation of the study is that the patient's level of adherence to lifestyle changes is not established; these changes are crucial in regulating NAFLD and hypertension. While pharmacological methods are detailed, much research needs to be conducted to appropriately understand the effects of these interventions on this particular patient population.

Unanswered Questions:

There are several unsolved questions on the best way to care for patients with such a combination of chronic diseases.

- To be more specific, what is the best regimen to treat hypertension in the presence of chronic kidney disease and fatty liver disease?
- How do lifestyle changes influence the course of the two chronic diseases, especially in elderly patients?
- How can long-term patient adherence to lifestyle modifications be better supported in such complex cases?

Suggestions for Future Research:

More studies are thus necessary to assess the long-term outcomes of integrated care regimens of CAD, NAFLD, CKD, and hypertension in similar patient groups. Further research should focus on determining optimal drug combinations for patients suffering from chronic kidney disease and resistant hypertension.

VII. SUMMARY

This case proof focuses on internal medical management of a 65-year-old man with multiple coexisting conditions including hypertension that has been poorly controlled, stage 2 Chronic kidney disease(CKD), Non Alcoholic Fatty liver disease(NAFLD) and previous diagnosis of coronary artery stenting. Though he is on several antihypertensive drugs, he still does not have his hypertension under check. Signs are leg swelling, excessive weight gain and tiredness; biochemical test derangement includes raised creatinine, proteinuria as well as raised liver enzymes.

Management is directed toward improving antihypertensive treatment, especially ACE inhibitors or ARBs for hypertension and proteinuria and loop diuretics for fluid retention. Advisable changes in behavior include avoiding high salt intake and exercising for both hypertension and fatty liver disease. Statins are prescribed and maintained for cardiovascular risk reduction and patients require ongoing assessment of kidney, liver and cardiovascular functions.

The case also highlights the importance of a systemic coordinated approach focusing on pharmacotherapy as well as on lifestyle modifications. It also has implications for management of antihypertensive medications in patients with CKD and NAFLD and the durability of lifestyle changes in this population, and calls for additional investigation in these areas.

VIII. CONCLUSION

Therefore, this case demonstrates the complex process of caring for a patient with multiple comorbidities mainly hypertension, chronic kidney disease, fatty liver disease, and coronary artery disease. One condition enables the other, we observe a perfect synergy, therefore, it calls for holistic and synchronized management. In general, fine-tuning antihypertensive therapy and preserving renal and hepatic reserve requires a careful selection of drugs and non-drug interventions. Everyone needs close follow-up and dose adjustments to avoid subsequent cardiovascular events. The case advocates for individual patient management as a highly coordinated approach can make a large difference and recommends that more research be done into better therapeutic regimens appropriate for complicated, multiple-illness patients such as this one.



REFERENCES

[1]. Chalasani N, Younossi Z, Lavine JE, Charlton M, Sanyal AJ. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328-57. https://aasldpubs.onlinelibrary.wiley.com/doi/10.1002/hep.29367

[2]. Collins R, Reith C, Emberson J. Effects of statin-based interventions for the prevention of stroke. Lancet Neurol. 2016;15(5):523-30. https://www.sciencedirect.com/science/article/pii/S1474442216000566]

[3]. KDIGO. KDIGO 2020 Clinical Practice Guideline for Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl. 2020;10(4) https://www.kidney-international.org/article/S2468-0249(20)30143-8/fulltext

[4]. Kovesdy CP, Appel LJ, Grams ME. Management of hypertension and kidney disease: Integrating and optimizing current treatment strategies. Am J Kidney Dis. 2017;69(4):510-23. https://www.ajkd.org/article/S0272-6386(16)30730-4/fulltext

[5]. Mancia G, Fagard R, Narkiewicz K, Redon J. 2013 ESH/ESC Guidelines for the management of arterial hypertension. Eur Heart J. 2013;34(28):2159-219. https://academic.oup.com/eurheartj/article/34/28/2159/455938

[6]. 1. Tabashnik BE, Zhang M, Fabrick JA, Wu Y, Gao M, Huang F, et al. Dual mode of action of BT proteins: Protoxin efficacy against resistant insects [Internet]. U.S. National Library of Medicine; 2015 [cited 2024 Sept 7]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4601037/

[7]. Lahoz-García N, García-Hermoso A, Milla-Tobarra M, Díez-Fernández A, Soriano-Cano A, Martínez-Vizcaíno V. Cardiorespiratory Fitness as a Mediator of the Influence of Diet on Obesity in Children. Nutrients [Internet]. 2018 Mar 1 [cited 2022 Mar 27];10(3):358. https://www.mdpi.com/2072-6643/10/3/358/htm

[8]. Lütje S, Feldmann G, Essler M, Brossart P, Bundschuh RA. Immune Checkpoint Imaging in Oncology: A Game Changer Toward Personalized Immunotherapy? Journal of Nuclear Medicine [Internet]. 2020 Jan 10 [cited 2023 Mar 5];61(8):1137–44. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413235/

[9]. Gosse, P., Dauphinot, V., Roche, F., Pichot, V., Celle, S., & Barthelemy, J. (2009). Prevalence of clinical and ambulatory hypertension in a population of 65-Year-Olds: the PROOF Study. *Journal of Clinical Hypertension*, *12*(3), 160–165. https://doi.org/10.1111/j.1751-7176.2009.00235.x

[10]. Ma, C., Yan, K., Wang, Z., Zhang, Q., Gao, L., Xu, T., Sai, J., Cheng, F., & Du, Y. (2021). The association between hypertension and nonalcoholic fatty liver disease (NAFLD): literature evidence and systems biology analysis. *Bioengineered*, *12*(1), 2187–2202. https://doi.org/10.1080/21655979.2021.1933302

[11]. Carey, R. M., Wright, J. T., Jr, Taler, S. J., & Whelton, P. K. (2021). Guideline-Driven Management of Hypertension: An Evidence-Based Update. *Circulation research*, *128*(7), 827–846. https://doi.org/10.1161/CIRCRESAHA.121.318083

[12]. Kitt, J., Fox, R., Tucker, K. L., & McManus, R. J. (2019). New Approaches in Hypertension Management: a Review of Current and Developing Technologies and Their Potential Impact on Hypertension Care. *Current hypertension reports*, *21*(6), 44. https://doi.org/10.1007/s11906-019-0949-4

[13]. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cífková R, Dominiczak AF, Grassi G, Jordan J, Poulter NR, Rodgers A, Whelton PK. Hypertension. Nat Rev Dis Primers. 2018 Mar 22;4:18014. doi: 10.1038/nrdp.2018.14. PMID: 29565029; PMCID: PMC6477925.

[14]. *Risk Factors in Hypertension : Journal of Cardiovascular Pharmacology*. (n.d.). LWW. https://journals.lww.com/cardiovascularpharm/abstract/1989/00131/Risk_Factors_in_Hypertension.3.aspx

[15]. Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, et al. Association of Non-Alcoholic Fatty Liver Disease With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Public Library of Science [Internet]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4106719/

[16]. Marcuccilli M, Chonchol M. NAFLD and Chronic Kidney Disease. Multidisciplinary Digital Publishing Institute [Internet]. https://www.mdpi.com/1422-0067/17/4/562

[17]. Kumar A, Yadav A, Rani S, Singh R, Kumar A, Gupta R. COVID-19: A Review of Its Impact on Health Care and Medical Education. *J Med Internet Res*. 2021;23(6). doi:10.2196/27261. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8448161/

[18]. Ibragimov A, Rahmatov N, Tashkentov D, et al. The impact of the COVID-19 pandemic on the mental health of healthcare workers in Uzbekistan. *Eur J Med Res*. 2023;28(1):114. doi:10.1186/s40001-023-01114-6. https://eurjmedres.biomedcentral.com/articles/10.1186/s40001-023-01114-6.

[19]. Lunev A, Sokolova N, Stetsenko I. Digitalization of agro-industrial complex as a basis for building organizational-economic mechanism of sustainable development: foreign experience and perspectives in Russia. https://www.researchgate.net/publication/335830132_Digitalization_of_Agro-Industrial_Complex_as_a_Basis_for_Building_Organizational-Economic_Mechanism_of_Sustainable_Development_Foreign_Experience_and_Perspectives_in_Russia.

[20]. Shah AG, Lydecker A, Murray K, et al. Compensation for the increasing prevalence of nonalcoholic fatty liver disease in the United States. *Hepatology*. 2018;67(4):1400-1411. doi:10.1002/hep.29531456. https://pubmed.ncbi.nlm.nih.gov/29531456/

[21]. Mokdad AH, Forouzanfar MH, Daoud F, et al. The impact of nonalcoholic fatty liver disease on cardiovascular and renal outcomes in older adults: A systematic review. *BMC Geriatr*. 2021;21(1):216. doi:10.1186/s12877-021-02175-1. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8001920/

[22]. Pugh D, Gallacher PJ, Dhaun N. Management of hypertension in chronic kidney disease - drugs [Internet]. Springer International Publishing; 2020 [cited 2024 Oct 10]. Available from: https://link.springer.com/article/10.1007/s40265-019-1064-1